Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naoqing Zhiming (脑晴智明) is an investigational botanical drug candidate developed by Beijing Huayi Shennong Pharmaceutical Technology for the treatment of vascular dementia. Classified as a Class 1.1 innovative Traditional Chinese Medicine (TCM) in China, it is formulated as an oral tablet. The drug is designed to address cognitive impairment associated with vascular brain injury, likely through neuroprotective and vasoactive mechanisms common to its botanical constituents. Clinical evaluation, including Phase I safety and pharmacokinetic studies, has been conducted in healthy subjects to determine the maximum tolerated dose and recommended Phase II dose.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Naoqing Zhiming.